PCN118 - The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia
- Resource Type
- Abstract
- Source
- In
Value in Health October-November 2017 20(9):A433-A433 - Subject
- Language
- ISSN
- 1098-3015